Log in | Register

Cost-effectiveness of the Surviving Sepsis Campaign protocol for severe sepsis: a prospective nation-wide study in Spain

David Suarez| Ricard Ferrer| Antonio Artigas| Izaskun Azkarate| José Garnacho-Montero| Gemma Gomà| Mitchell M. Levy| Juan Carlos Ruiz
Original
Volume 37, Issue 3 / March , 2011

Pages 444 - 452

Abstract

Context

Severe sepsis is associated with high mortality and increased costs. The ‘Surviving Sepsis Campaign’ (SSC) protocol was developed as an international initiative to reduce mortality. However, its cost-effectiveness is unknown.

Objective

To determine the cost-effectiveness of the SSC protocol for the treatment of severe sepsis in Spain after the implementation of an educational program compared with the conventional care of severe sepsis.

Design

Observational prospective before-and-after study.

Setting

59 medical-surgical intensive care units located throughout Spain.

Patients

A total of 854 patients were enrolled in the pre-educational program cohort (usual or standard care of severe sepsis) and 1,465 patients in the post-educational program cohort (SSC protocol care of severe sepsis).

Interventions

The educational program aimed to increase adherence to the SSC protocol. The SSC protocol included pharmacological and medical interventions.

Main outcome measures

Clinical (hospital mortality) and economic (health-care resource and treatment costs) outcomes were recorded. A health-care system perspective was used for costs. The primary outcome was incremental cost-effectiveness ratio (ICER).

Results

Patients in the SSC protocol care cohort had a lower risk of hospital mortality (44.0% vs. 39.7%, P = 0.04). However, mean costs per patient were 1,736 euros higher in the SSC protocol care cohort (95% CI 114–3,358 euros), largely as a result of increased length of stay. Mean life years gained (LYG) were higher in the SSC protocol care cohort: 0.54 years (95% CI 0.02–1.05 years). The adjusted ICER of the SSC protocol was 4,435 euros per LYG. Nearly all (96.5%) the bootstrap replications were below the threshold of 30,000 euros per LYG.

Conclusion

The SSC protocol seems to be a cost-effective option for treating severe sepsis in Spain.

Keywords

References

  1. Martin GS, Mannino DM, Eaton S, Moss M (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348:1546–1554
    • View reference on publisher's website
    • View reference on PubMed
  2. Brun-Buisson C, Doyon F, Carlet J, Dellamonica P, Gouin F, Lepoutre A, Mercier JC, Offenstadt G, Regnier B (1995) Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA 274:968–974
    • View reference on publisher's website
    • View reference on PubMed
  3. Guidet B, Aegerter P, Gauzit R, Meshaka P, Dreyfuss D (2005) Incidence and impact of organ dysfunctions associated with sepsis. Chest 127:942–951
    • View reference on publisher's website
    • View reference on PubMed
  4. Esteban A, Frutos-Vivar F, Ferguson ND, Penuelas O, Lorente JA, Gordo F, Honrubia T, Algora A, Bustos A, Garcia G, Diaz-Reganon IR, de Luna RR (2007) Sepsis incidence and outcome: contrasting the intensive care unit with the hospital ward. Crit Care Med 35:1284–1289
    • View reference on publisher's website
    • View reference on PubMed
  5. Blanco J, Muriel-Bombin A, Sagredo V, Taboada F, Gandia F, Tamayo L, Collado J, Garcia-Labattut A, Carriedo D, Valledor M, De Frutos M, Lopez MJ, Caballero A, Guerra J, Alvarez B, Mayo A, Villar J (2008) Incidence, organ dysfunction and mortality in severe sepsis: a Spanish multicentre study. Crit Care 12:R158
    • View reference on PubMed
  6. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL (2008) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 34:17–60
  7. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM (2004) Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 30:536–555
  8. Levy MM, Dellinger RP, Townsend SR, Marshall JC, Bion J, Schorr C, Artigas A, Parker MM, Gerlach H, Reinhart K, Silva E, Harvey M, Regan S, Angus DC (2010) The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med 36:222–231
  9. Ferrer R, Artigas A, Levy MM, Blanco J, Gonzalez-Diaz G, Garnacho-Montero J, Ibanez J, Palencia E, Quintana M, de la Torre-Prados MV (2008) Improvement in process of care and outcome after a multicenter severe sepsis educational program in Spain. JAMA 299:2294–2303
    • View reference on publisher's website
    • View reference on PubMed
  10. Inigo J, Sendra JM, Diaz R, Bouza C, Sarria-Santamera A (2006) Epidemiology and costs of severe sepsis in Madrid. A hospital discharge study. Med Intensiva 30:197–203
    • View reference on publisher's website
    • View reference on PubMed
  11. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:1303–1310
    • View reference on publisher's website
    • View reference on PubMed
  12. Levy MM, Fink MP, Marshall JC, Angus DC, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G (2003) International Sepsis Definitions Conference. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 29:530–538
    • View reference on PubMed
  13. National Statistics Institute. Mortality tables for the population of Spain. http://www.ine.es/jaxi/menu.do?L=1&type=pcaxis&path=%2Ft20%2Fp319a&file=inebase&L=. Accessed 24 Oct 2008
  14. Quartin AA, Schein RM, Kett DH, Peduzzi PN (1997) Magnitude and duration of the effect of sepsis on survival. Department of Veterans Affairs Systemic Sepsis Cooperative Studies Group. JAMA 277:1058–1063
    • View reference on publisher's website
    • View reference on PubMed
  15. Angus DC, Linde-Zwirble WT, Clermont G, Ball DE, Basson BR, Ely EW, Laterre PF, Vincent JL, Bernard G, van Hout B (2003) Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 31:1–11
    • View reference on publisher's website
    • View reference on PubMed
  16. Shorr AF, Susla GM, Kollef MH (2004) Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin. Crit Care Med 32:137–143
    • View reference on publisher's website
    • View reference on PubMed
  17. Talmor D, Greenberg D, Howell MD, Lisbon A, Novack V, Shapiro N (2008) The costs and cost-effectiveness of an integrated sepsis treatment protocol. Crit Care Med 36:1168–1174
    • View reference on publisher's website
    • View reference on PubMed
  18. Drabinski A, Williams G, Formica C (2001) Observational evaluation of the health state utilities among a cohort of sepsis patients. Value Health 4:128–129
    • View reference on publisher's website
  19. Brooks R, Rabin R, de Charro F (2003) The measurement and valuation of health status using EQ-5D: a European perspective. Kluwer Academic, Dordrecht
  20. Instituto Nacional de Salud. Resultados de la gestión analítica en los hospitales del Insalud 2000. http://www.ingesa.msc.es/estadEstudios/documPublica/pdf/gesAnalitica.pdf. Accessed 1 Dec 2008
  21. Vademecum International 2009. Medicom, Barcelona
  22. Van den Berghe G, Wouters PJ, Kesteloot K, Hilleman DE (2006) Analysis of healthcare resource utilization with intensive insulin therapy in critically ill patients. Crit Care Med 34:612–616
    • View reference on PubMed
  23. Organisation for Economic Co-operation and Development (OECD). OECD statistics on Purchasing Power Parities (PPP). http://www.oecd.org/dataoecd/61/56/39653523.xls. Accessed 15 Dec 2008
  24. Consumer Price Index. National Statistics Institute. http://www.ine.es/en/daco/ipc_en.htm. Accessed 24 Oct 2008
  25. Jegers M, Edbrooke DL, Hibbert CL, Chalfin DB, Burchardi H (2002) Definitions and methods of cost assessment: an intensivist’s guide. ESICM section on health research and outcome working group on cost effectiveness. Intensive Care Med 28:680–685
  26. Efron B, Tibshirani R (1993) An introduction to the Bootstrap. Chapman & Hall/CRC, Boca Raton
  27. Coughlin MT, Angus DC (2003) Economic evaluation of new therapies in critical illness. Crit Care Med 31:S7–S16
    • View reference on publisher's website
    • View reference on PubMed
  28. Manning WG, Mullahy J (2001) Estimating log models: to transform or not to transform? J Health Econ 20:461–494
    • View reference on publisher's website
    • View reference on PubMed
  29. Glick HA, Doshi JA, Sonnad SS, Polsky D (2007) Economic evaluation in clinical trials. Oxford University Press, New York
  30. Localio AR, Berlin JA, Ten Have TR, Kimmel SE (2001) Adjustments for center in multicenter studies: an overview. Ann Intern Med 135:112–123
    • View reference on PubMed
  31. Sacristan JA, Oliva J, Del Llano J, Prieto L, Pinto JL (2002) What is an efficient health technology in Spain? Gac Sanit 16:334–343
    • View reference on PubMed
  32. Karlsson S, Ruokonen E, Varpula T, Ala-Kokko TI, Pettila V (2009) Long-term outcome and quality-adjusted life years after severe sepsis. Crit Care Med 37:1268–1274
    • View reference on publisher's website
    • View reference on PubMed
  33. Shorr AF, Micek ST, Jackson WL Jr, Kollef MH (2007) Economic implications of an evidence-based sepsis protocol: can we improve outcomes and lower costs? Crit Care Med 35:1257–1262
    • View reference on publisher's website
    • View reference on PubMed
  34. Sacristan JA, Prieto L, Huete T, Artigas A, Badia X, Chinn C, Hudson P (2004) Cost-effectiveness of drotrecogin alpha (activated) in the treatment of severe sepsis in Spain. Gac Sanit 18:50–57
    • View reference on publisher's website
    • View reference on PubMed
  35. Talmor D, Shapiro N, Greenberg D, Stone PW, Neumann PJ (2006) When is critical care medicine cost-effective? A systematic review of the cost-effectiveness literature. Crit Care Med 34:2738–2747
    • View reference on publisher's website
    • View reference on PubMed
  36. Suarez D, Haro JM, Novick D, Ochoa S (2008) Marginal structural models might overcome confounding when analyzing multiple treatment effects in observational studies. J Clin Epidemiol 61:525–530
    • View reference on publisher's website
    • View reference on PubMed
  37. Kahn JM, Bates DW (2008) Improving sepsis care: the road ahead. JAMA 299:2322–2323
    • View reference on publisher's website
    • View reference on PubMed

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement